Epstein-Barr virus (EBV) infects cells in latent or lytic forms, but the role of lytic infection in EBV-
Epstein-Barr virus (EBV) is a human herpesvirus that causes infectious mononucleosis and is associated with both B cell and epithelial-cell malignancies (20, 32) . EBV-positive B cell lymphomas include endemic Burkitt lymphoma (BL), Hodgkin lymphoma (HL), lymphoproliferative disease (LPD) in immunocompromised hosts (32) , and diffuse large B cell lymphomas (DLBCL), particularly in elderly patients and AIDS patients (29, 30) . EBV does not infect rodent cells, making it difficult to study EBV pathogenesis and EBV-induced lymphomas by using small-animal models. EBV-positive transformed B cell lines (lymphoblastoid cell lines [LCLs] ) can be grown in SCID mice, but these animals do not have a functional immune system and cannot model the different human B cell differentiation states seen in various types of EBVpositive tumors. Recently, mice with partially reconstituted human immune systems from engraftment of human CD34 ϩ hematopoietic stem cells (HSCs) have provided improved models for studying EBV pathogenesis (4, 38, 43, 44) .
A critical advantage of these new model systems is the ability to investigate the role of different forms of viral infection (e.g., latent versus lytic) in the context of selective pressure exerted by the host immune system. This is important because multiple viral and host factors likely determine whether EBV-infected B cells eventually proliferate into lymphomas, and the relative contributions of different factors are not well understood. For example, EBV-positive lymphomas primarily contain cells showing latent forms of infection, but the role of lytic infection in their genesis is unclear. Lytic infection kills the host cell; however, it also allows horizontal spread of EBV from cell to cell and may increase the pool of latently infected B cells from which transformed cells arise. Chronic acyclovir therapy in patients treated for herpes simplex virus reactivation also decreases EBV viral loads (14) , suggesting that horizontal EBV transmission may be required to replenish the reservoir of latently infected cells. Consistent with a tumorigenic role for lytic infection, prophylactic treatment of transplant patients with antiviral drugs that inhibit lytic replication may reduce EBV-associated lymphomas (6, 10) . Moreover, LCLs derived from a lytic replication-defective EBV mutant have an impaired ability to form LPD-like lesions in SCID mice (12) . Additionally, lytically infected B cells secrete factors that may promote B cell tumors through a variety of mechanisms, including the B cell growth factor interleukin 6 (IL-6) (18), two different angiogenesis factors (vascular endothelial growth fac-tor [VEGF] and IL-8) (13, 15) , and immunosuppressive cytokines (cellular IL-10 [23, 37] , viral IL-10 [25, 39] , and transforming growth factor ␤ [TGF-␤] [2] ). The major counterbalancing element to EBV-driven lymphomagenesis is the host immune response. Much of the human T cell response to EBV is directed against lytic viral proteins (36), as well as against latency proteins that are associated with more aggressive B cell proliferation (3) , and thus host immune activity probably particularly limits these highly pathogenic forms of viral infection. Several different types of EBV latency have been described, each characterized by different patterns of EBV gene expression and corresponding differences in immunogenicity (20) . Type III latency, in which all 9 latent viral proteins are made, is the only type able to transform primary B cells in vitro; however, this type of infection is highly immunogenic, and tumors with type III latency are usually observed only in immunosuppressed patients (5, 11) . At the other end of the spectrum are the type 0/type I forms of latency, in which either no viral protein (type 0) or only EBNA1 (type I) is expressed. Cells with this type of latency persist throughout life in the peripheral memory B cell compartment following recovery from primary EBV infection; type I latency is also found in EBV-positive Burkitt lymphomas (40) . Cells with type IIA latency (EBNA1 ϩ /LMP1 ϩ /EBNA2 Ϫ ) are found in memory B cells and germinal center cells in the tonsils of healthy EBV carriers, as well as in EBV-positive Hodgkin lymphomas (41) . Cells with type IIB latency (EBNA1 ϩ /EBNA2 ϩ /LMP1 Ϫ ) are found in the tonsils of patients with infectious mononucleosis (22, 27) but have not yet been reported to be the predominant form of infection in any type of EBV-positive human tumor. Thus far, animal models of EBV infection have demonstrated a predominance of type III latency, and it has been difficult to model types 0, I, IIA, and IIB, perhaps because the immune responses in these models have not provided sufficient control of cells with type III latency to allow for the outgrowth of the other less aggressive latency forms.
In the current study, we investigate the role of lytic viral infection in EBV pathogenesis and tumorigenesis by testing a lytic replication-defective EBV mutant compared to a lytically active control strain. We use a new humanized NOD/LtSz-scid/ IL2R␥ null (hNSG) mouse model, in which both human CD34 ϩ hematopoietic stem cells and human thymus/liver tissue are engrafted. This model allows for the development of human T cells that are restricted by the major histocompatibility complex (MHC) molecules expressed by their autologous B cells, which is critical for efficient immune control of EBV infection. Thus, the analysis presented here provides the first assessment of the impact of lytic viral infection on lymphoma development within the context of a self-educated human immune system.
MATERIALS AND METHODS
Humanized NOD/LtSz-scid/IL2R␥ null mice. Immunodeficient nonobese diabetic/severe combined immunodeficient (NOD/LtSz-scid/IL2R␥
null [NSG] ) mice were purchased from Jackson Labs (catalogue no. 005557) and used at 6 to 10 weeks of age. Human fetal thymus and liver tissues (gestational age, 17 to 20 weeks) were obtained from Advanced Bioscience Resource (Alameda, CA). Mice were humanized by following the procedure described previously (31) . In brief, the recipient mice were conditioned with sublethal (2 to 3 Gy) whole-body irradiation and implanted with fetal thymus and liver fragments under the recipient kidney capsule after irradiation. The mice also received an intravenous injection of purified CD34 ϩ cells isolated from the same fetal liver by the magnetically activated cell sorter (MACS) separation system (Miltenyi Biotec, Auburn, CA). The purity of the injected CD34 ϩ cells was at least 80 to 90%. At 10 weeks after immune reconstitution, the levels of human hematopoietic cells in mice were determined by multicolor flow cytometric (FCM) analysis using various combinations of the following antibodies: pan-anti-CD45 (clone HI30), -CD4 (clone RPA-T4 or OKT4), -CD8␣ (clone RPA-T8), -CD19 (HIB19), and -CD3 (SP34-2). Antibodies directly conjugated to fluorescent dyes were purchased from commercial sources. For flow cytometric analysis, blood was collected from mice 10 weeks after implantation of human cells. Samples were subjected to ACK lysis to remove red blood cells and further purified by density gradient centrifugation using Histopaque (Sigma). Fluorescence-activated cell sorting (FACS) analysis was performed on a FACSCalibur (Becton Dickinson, Mountain View, CA). Dead cells were excluded from the analysis.
In one experiment, humanized mice were made without cotransplanting fetal thymic tissue. In brief, NSG mice were irradiated with 2 Gy 24 to 48 h after birth, and purified fetal liver CD34 ϩ cells (0.5 million) were injected intrahepatically into each mouse. Immune reconstitution was documented as above.
Viruses and plasmids. Wild-type (WT) EBV (B95-8 strain), expressing the green fluorescent protein (GFP) and a hygromycin B resistance gene, and the BZLF1-deleted mutant virus (Z-KO) were constructed using bacterial artificial chromosome technology as described previously (7, 8) and were a gift from Henri-Jacques Delecluse. WT and Z-KO 293 cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and hygromycin B (100 g/ml; Roche). Raji, an EBV-positive Burkitt lymphoma cell line, was maintained in RPMI 1640 medium with 10% FBS and 1% penicillin-streptomycin. Plasmid DNA was purified through columns as described by the manufacturer (Qiagen). The EBV pSG5-BZLF1 and pSG5-gp110 expression vectors were gifts from Diane Hayward (34) and Henri-Jacques Delecluse (26) , respectively.
EBV infection of mice. 293 cells latently infected with the WT or Z-KO viruses were converted to the lytic form of EBV infection by transfecting them with BZLF1 and gp110 expression vectors by using the FuGENE 6 transfection reagent (Roche) as per the manufacturer's protocol. Supernatants were harvested at 72 h posttransfection and filtered through a 0.45-um-pore-size filter. The virus was concentrated by centrifuging at 18,000 rpm for 3 h using an SW27 rotor, resuspended in phosphate-buffered saline (PBS) overnight at 4°C, and then stored at Ϫ80°C. To determine the titer of the EBV stock, Raji cells were infected with serial 10-fold dilutions of virus. After 48 h, cells were treated with 50 ng/ml phorbol-12-myristate-3-acetate (PMA; Sigma) and 3 mM sodium butyrate (Sigma), and the GFP-expressing Raji cells were counted 24 h later by fluorescence microscopy. The amount of virus required to form one GFP-positive Raji cell was defined as one green Raji unit (GRU).
Mice were injected intraperitoneally (i.p.) with 2,750 GRUs of WT or Z-KO EBV in 250 l PBS or mock infected with PBS alone. In most experiments, half of the mice derived from a particular donor (8 to 12 mice per donor) were infected with the WT virus, and the other half were infected with the Z-KO virus. In one experiment, half of the mice reconstituted with a particular donor were infected with the Z-KO virus, and the other half were mock infected (and thus more animals were infected with Z-KO virus than with the control WT virus). One WT EBV-infected animal and one Z-KO virus-infected animal were sacrificed at days 3 and 20 postinfection, and the rest of the animals were sacrificed at 60 to 65 days postinfection unless they exhibited clinical signs, including weight loss, disturbed gait, or hair loss. Organs, including spleen, lymph node, lung, liver, pancreas, kidney, heart, implanted human fetal thymus, head, bone marrow, muscle, stomach, bowel, and salivary gland, were collected and fixed with 10% formalin and then paraffin embedded.
Detection of EBV-encoded RNAs (EBERs) by in situ hybridization. EBER in situ hybridization studies were performed using the PNA ISH detection kit (DakoCytomation) according to the manufacturer's protocol. Briefly, tissues were deparaffinized and rehydrated and then treated with 1:10 diluted proteinase K at room temperature for 20 min. After tissues were washed, EBER probe was added on top of the tissue and covered with a cover slide. Hybridization was performed at 55°C for 90 min. After hybridization, tissues were washed with stringent washing solution at 55°C for 30 min. Anti-fluorescein isothiocyanate (anti-FITC)/AP was added and incubated at room temperature for 30 min, and substrate was then added to develop the color. Tissues were counterstained with nuclear fast red. To compare the number of EBV-infected cells in animals infected with the WT versus that in animals infected with the Z-KO virus, we calculated the number of EBER-positive cells in each mouse by counting the positive cells in slides that included sections containing the kidney, liver, implanted fetal thymus, spleen, and lung from each animal. Although other tissues or organs, such as lymph nodes, also contained some EBER-positive cells, since these tissues were not consistently present on the slides of all animals, they were excluded in the comparison.
Measurement of EBV viral loads. Plasma samples (approximately 100 l) were collected from jugular vein bleeds after euthanasia of animals and frozen. DNA was extracted using the QIAamp DNA minikit and eluted in 100 l nuclease-free water. Five microliters of the DNA was applied in duplicate quantitative PCR (Q-PCR) targeting the EBV BamH1W segment [EBV W1, 5Ј-GCAGCCGCC CAGTCTCT-3Ј; EBV W2, 5Ј-ACAGACAGTGCACAGGAGCCT-3Ј; and EBVWprobe, 5Ј-(6-carboxyfluorescein)AAAAGCTGGCGCCCTTGCCTG(6-carboxytetramethylrhodamine)-3Ј] as previously described (33) . Human ApoB DNA was quantitated in a separate well as a marker of the efficacy of extraction and amplification. The EBV PCR assay has a sensitivity of 6 copies per PCR.
Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue sections and cells were deparaffinized and hydrated and then treated with 10 mM citrate buffer (0.05% Tween 20, pH 6.0) for 20 min in a water bath at 98°C. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxidase solution, and nonspecific labeling was blocked in a 5% goat serum blocking solution. Sections were incubated with the first antibody for 1 h at room temperature. The Super Sensitive polymer-horseradish peroxidase immunohistochemistry detection system (BioGenex Inc.) was used by following the manufacturer's instruction. Colors were developed with the diaminobenzidine tetrachloride (DAB) substrate kit (Vector Laboratories Inc.) by following the manufacturer's instruction. In the cases of double staining, a combination of the DAB substrate kit (nickel solution was added to DAB) and the Vector VIP substrate kit (Vector Laboratories Inc.) was used by following the manufacturer's instruction. Antibodies (and dilutions) used were as follows T cell proliferation assays. hNSG mice were infected with 2,750 GRUs of WT or Z-KO EBV suspended in PBS or mock treated with PBS alone. Twenty to 35 days postinfection, animals were sacrificed and splenocytes were harvested. The splenocytes were depleted of B cells by magnetic sorting using anti-CD19 beads (Miltenyi Biotech) and labeled with 2.5 M carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes, Eugene, OR). Autologous uninfected B cells, or lymphoblastoid cell lines (LCLs) made by infecting autologous B cells with WT EBV or Z-KO EBV, were ␥-irradiated (7,500 rads) and cultured with the CFSElabeled splenic cells at a ratio of 1:50. After 7 to 8 days of culture, the cells were fluorescently stained for expression of CD3 to identify T cells, treated with DAPI (4Ј,6-diamidino-2-phenylindole) to allow for the exclusion of dead cells, and analyzed by flow cytometry. The percentage of T cells that had undergone cell division was determined by gating on DAPI-negative CD3-positive cells and assessing the fraction that showed diminished CFSE fluorescence intensity.
T cell killing assays. Splenocytes from WT or Z-KO EBV-infected or mocktreated mice were magnetically depleted of B cells and labeled with CFSE as described above. The splenic cells were incubated in culture medium at 37°C at a 3:1 ratio with autologous uninfected B cells or LCLs made by infecting the B cells with WT EBV or Z-KO EBV. In parallel, uninfected B cells or WT or Z-KO LCLs were incubated alone (without splenic effector cells) to assess the amount of spontaneous cell killing. After 4 h, the cultures were stained with DAPI to identify dead or dying cells and analyzed by flow cytometry. Percent target cell killing was assessed for each culture by determining the fraction of the total CFSE-negative population that showed elevated DAPI staining. Specific killing was calculated by subtracting the amount of spontaneous cell death of target cells alone from the amount of cell death observed in the presence of splenic effector cells.
Delayed-type hypersensitivity (DTH) assay. WT or Z-KO EBV-infected thymus-engrafted hNSG(thy) mice (four animals each) and two mock-infected hNS-G(thy) mice were subcutaneously injected into the right hind footpad with 12.5 g of commercially available EBV antigens (Meridian Life Science, Inc., Memphis, TN) in a total volume of 25 l 1 month postinfection. To control for swelling caused by the injection itself, PBS alone was injected into the left hind footpad. The hind footpad thickness was measured 24 h postinjection by using a dial thickness gauge. The preinjection measurement was subtracted from the postinjection measurement to obtain specific swelling values. DTH reactivity is shown as the change in thickness of the hind footpad expressed in units of 10
Ϫ4
inches.
RESULTS
Successful multilineage human hematopoietic reconstitution and thymic engraftment of NSG mice. To generate an in vivo model that would allow analysis of EBV pathogenesis and lymphoma formation in the context of a self-educated human immune system, we injected irradiated NSG mice intravenously (i.v.) with human fetal CD34 ϩ cells (purified from fetal liver) and cotransplanted a small piece of the fetal thymus (with liver tissue) under the kidney capsule, as previously described (31) . Reconstitution levels of human cells in the NSG mice were determined using multicolor flow cytometric analysis at 10 weeks posttransplantation. At the time point of EBV infection (10 to 12 weeks after engraftment), human-derived CD45 cells comprised around 35% of the total leukocyte population, and both T cells (including CD4-and CD8-positive cells) and B cells were present (Fig. 1) . In addition, the engrafted human thymic tissue remained viable under the mouse kidney capsule for the duration of the experiments.
Both the control EBV and a lytic replication-defective mutant establish long-term latency in hNSG(thy) mice and traffic to similar sites. To directly test the role of lytic infection in the pathogenesis of EBV infection, we compared a lytically active control virus to a deletion mutant strain (Z-KO) lacking BZLF1, a transcription factor required for lytic viral gene expression (20, 32) . The Z-KO virus contains a kanamycin resistance cassette (inserted between nucleotides 102389 to 103388 using B95.8 coordinates) that specifically disrupts BZLF1 function, and the phenotype of the mutant virus can be rescued in trans by the expression of the BZLF1 gene product (7, 8) . Immune reconstituted mice were infected i.p. with equal titers of the control or Z-KO virus and sacrificed at various EBER-positive cells were found in the tissues from uninfected hNSG(thy) animals (data not shown).
To determine if horizontal viral transmission is required for the ability of EBV to infect certain cell types or to reach certain sites in the body, we compared the sites of EBER-positive cells in tumor-free animals infected with the control or Z-KO virus. EBER-positive cells were most frequently observed in the liver, spleen, kidney, lung, and transplanted human thymic tissue (Table 1) . In some animals, EBER-positive cells were found in the bone marrow, nasal lymphoid tissues, mesentery, and muscle tissue ( Fig. 2 and data not shown) . In the transplanted fetal thymus, EBV-positive cells were most commonly found in the medulla area, often near Hassall's corpuscles (Fig.  3A) . In the spleen, EBV-positive cells were usually located within CD20-rich lymphoid zones (Fig. 3B) . No clear differences in the sites and numbers of EBER-positive cells were observed in animals infected with the control virus or the Z-KO virus (Table 1) . Although Z-KO-infected animals were somewhat more likely than control virus-infected animals to have EBV-infected B cells in the thymus and spleen, the differences were not statistically significant. Since the Z-KO virus is not horizontally transmitted, these results indicate that EBV-infected B cells home to many different organs in this model and that transmission of EBV from cell to cell via the (35) and is found in some T cell and NK cell lymphomas (17) . To determine if EBV can infect cell types other than B cells in the hNSG(thy) mouse model, we costained multiple tissues using an anti-EBNA1 antibody and antibodies specific for human B cells (CD20), T cells (CD3), monocytes (CD14 and CD68), hematopoietic stem cells (CD34), and epithelial cells (anticytokeratin). All EBNA1-positive cells costained with CD20 in every organ, including the transplanted human thymus (Fig. 4A) . Some EBNA1-positive cells also costained with anti-CD27, a marker for memory B cells (Fig. 4B) . Thus, few if any T cells or monocytes are infected with either the control or Z-KO EBV in this model.
EBV establishes type I and type IIB latency in hNSG(thy) mice. To define the type(s) of viral latency established by the control and Z-KO EBV, we performed an IHC assay in EBER-positive areas from multiple different types of organs in tumor-free animals, using anti-EBNA1, anti-EBNA2, and anti-LMP1 antibodies. As summarized in Table 2 , type I and type IIB latency were the most common forms of EBV infection in both the control virus-infected and Z-KO-infected mice. As we were unable to perform EBER in situ hybridization assays on the same cells used to perform EBNA IHC assays (due to loss of EBNA1 IHC staining under the EBER staining conditions and vice versa), we could not determine how many cells had type 0 latency. However, since we generally found more EBER-positive cells than EBNA1-positive cells in the tumorfree animals (data not shown), cells with type 0 latency may have also been present. Some animals had a mixture of various different types of latency depending upon the location. An example of cells with type I latency is shown in Fig. 5A , and examples of cells with type IIB latency are shown in Fig. 5B to D. Latent membrane protein 1 (LMP1)-positive cells were rare and/or nonexistent in most tumor-free hNSG(thy) animals infected with either the control or Z-KO EBV. Rare LMP1 ϩ / EBNA2
Ϫ cells (type IIA latency) were found in the kidney of a control EBV-infected mouse (Fig. 6A) . In tumor-free animals, cells with type III latency were observed most frequently at the day 20 time point ( Fig. 6B and C) . Thus, in animals that successfully limit their EBV infection, type III latency is transient, presumably because the host immune response eliminates cells with type III latency.
Fewer lymphomas develop in Z-KO-infected hNSG(thy) mice. Although many mice had asymptomatic infection, some EBV-infected mice eventually developed B cell lymphomas in this model. Importantly, the lytic replication-defective Z-KO virus produced significantly fewer lymphomas than the control virus. Six of the 11 mice infected with the control virus developed lymphomas, versus only 2 of the 14 Z-KO virus-infected animals (P Ͻ 0.05) (Fig. 7A) . All EBV-positive tumors were CD20 ϩ DLBCL-like lymphomas. A number of the EBV-induced lymphomas in this model were small and discovered only after review of a series of slide sections obtained from multiple different organs. Interestingly, in contrast to the EBVinduced lymphomas found in humanized mouse models that do not include engrafted human thymic tissue, which have all been reported to have type III latency (4, 38, 43), we found that some of the lymphomas in this hNSG(thy) model had type I (Fig. 7B ) and type IIB (Fig. 7C ) latency, although others did have type III latency (Fig. 7D ) (summarized in Table 3 ). No uninfected mice developed lymphomas (data not shown). These results suggest that one or more lytic viral proteins enhance the development of B cell lymphomas in the hNSG(thy) mouse model and show that this model provides for the development of EBV-positive lymphomas with type I and type IIB latency. 
Lytically infected cells in tumors of mice infected with the control virus.
To examine the effect of lytic viral infection upon the level of EBV DNA in the plasma, we performed viral load assays in a subset of mock-and Z-KO and control virus-infected animals. Somewhat surprisingly, the only animal that had detectable viral DNA in the plasma was a control virusinfected animal with a large type III lymphoma (Table 4) . Although it is possible that EBV plasma viral loads might have been higher if measured at earlier time points after control virus infection, these results suggest that the development of an effective anti-EBV T cell response in this model acts to eliminate cells with lytic viral infection.
We also performed an IHC assay using antibodies directed against three different classes of lytic viral proteins (the immediate-early BZLF1 protein, the early BMRF1 protein, and the late gp350/220 protein) in all animals infected with the control EBV strain. Whereas no lytically infected cells were observed by IHC assay in any tissues from tumor-free mice (including the one animal examined at 3 days postinfection), rare cells expressing the BZLF1 and BMRF1 proteins, but not the gp350/220 protein, were found within B cell lymphomas (Fig.  8A) ; as expected, no BZLF1-or BMRF1-positive cells were found in any of the tumors infected with the Z-KO virus (data not shown). All BZLF1-positive cells costained with CD20 (data not shown), indicating that they were B cells. Notably, the absence of late viral antigen staining in the lymphoma cells suggests that lytic infection is either abortive or that cells expressing late viral proteins are rapidly eliminated. Interestingly, EBV infection of mice that were reconstituted with human CD34 ϩ stem cells in the absence of cotransplanted thymic tissue resulted in the development of tumors showing greater evidence of lytically infected cells (Fig. 8B) . Thus, the selfeducated T cells of the thymus-engrafted mice may contribute to the elimination of lytically infected cells.
Development of EBV-specific immune responses in hNSG (thy) mice. EBV-positive cells in tumor-free animals were almost always surrounded by CD3 ϩ T cells (Fig. 9A) , suggesting that T cells actively interact with EBV-infected B cells prior to tumor development. To investigate this directly, we assessed the responses of primary T cells from infected and uninfected mice to EBV-infected or uninfected B cells. Splenocytes from the control or Z-KO virus-infected or mock-infected mice were depleted of B cells and then labeled with CFSE and cultured with uninfected B cells or B cells that were infected in vitro with the control or Z-KO EBV (i.e., LCLs). After 7 to 9 days, the cultures were stained with anti-CD3 and DAPI and analyzed by flow cytometry for the percentage of live T cells that showed diminished CFSE fluorescence (indicating that cell division had taken place). As shown in Fig. 9B , T cells obtained from mice infected with either the Z-KO virus or the control virus showed significantly higher proliferation when exposed to EBV-infected B cells than when exposed to uninfected B cells. Additionally, T cells derived from mock-infected animals had minimal proliferative responses to the EBV-infected LCLs (Fig. 9B) . Thus, primary T cells from EBV-infected mice proliferated specifically in response to EBV-infected LCLs, whereas T cells from uninfected mice did not.
To further investigate the potential for immune-mediated control of EBV-infected cells in this model, cell killing assays were performed using splenic effector cells (e.g., T cells and NK cells) and uninfected B cells or LCLs infected with the control or Z-KO virus as target cells. As shown in Fig. 9C , in a 4-h assay, splenic effector cells from a mock-infected animal showed no specific killing of EBV-infected B cells (either control virus or Z-KO virus infected). In contrast, splenocytes from each of the two Z-KO virus-infected animals examined showed cytotoxic effector activity to both control virus-and Z-KO virus-infected LCLs, as did splenocytes from one of the two control virus-infected animals examined. There was no specific killing of uninfected B cells by effector cells from any of the animals, confirming that the cytotoxic response was specific to infected LCLs (Fig. 9C) . These results suggest that in this model, primary effector cells from EBV-infected animals can produce a functional killing response against EBVinfected B cells.
As another measure of the host immune response against EBV, we examined in vivo delayed-type hypersensitivity (DTH) responses to an antigen preparation from EBV-infected cells. DTH responses are localized inflammatory responses initiated by the activation of antigen-specific lymphocytes that result in multicellular infiltration and edema. Mice that were either mock infected or infected with the control or Z-KO virus were inoculated in the footpads with a preparation of protein antigens from a lytically induced EBV-positive cell line or PBS, and the amount of swelling in the footpads was measured 24 h later (Fig. 9D) . Both control EBV-and Z-KO virus-infected animals had significantly more swelling in response to the EBV antigen than the mock-infected animal. The DTH responses were not significantly different between control EBV-and Z-KO EBV-infected animals. This assay provides powerful confirmation that mice infected with either the control or ZKO virus strain develop in vivo immune responses against proteins from EBV-infected cells.
EBV-positive tumors of different latency types all attract a vigorous inflammatory response in hNSG(thy) mice. Finally, we stained tumors with anti-CD3 antibody (which recognizes all T cells), as well as anti-CD8 and anti-CD4 antibodies. All of the EBV-positive lymphomas, including those with type III latency (in which the immune response is obviously inadequate), were infiltrated with both CD4 ϩ and CD8 ϩ T cells in this model (Fig. 10A) . Interestingly, the CD4 cell infiltration of tumors with type IIB latency appeared particularly robust (Fig.  10B) . Levels of T cell infiltration of the tumors containing the control EBV versus the Z-KO virus were not obviously different. These results indicate that host T cells interact with various different types of EBV-positive tumors in this model, even when the tumors are not effectively eliminated.
DISCUSSION
The potential role of lytic viral infection in the development of various types of EBV-positive malignancies has remained unclear, in part due to the lack of suitable animal models to study this question. In addition, it has been difficult to study the role of the more restricted forms of viral latency in EBVpositive cancers using animal models, since EBV cannot infect rodent cells, and in the absence of a highly functional engrafted a Q-PCR was performed (using primers to detect the BamHI repeat region of the EBV sequence) on purified plasma DNA collected from mock-infected, control virus-infected, or Z-KO EBV-infected animals at the time points indicated. The human ApoB gene DNA was quantitated in a separate well as a marker of the efficacy of extraction and amplification. The presence (or absence) of tumors in each animal is indicated. DPI indicates the day postinfection that plasma was collected.
FIG. 7.
Control EBV infection induces more tumors than Z-KO virus infection in hNSG(thy) mice, and some EBV-positive tumors have restricted latency types. (A) The numbers of EBV-positive tumors in control and Z-KO virus-infected animals are shown (relative to the number of animals infected with each virus). The P value was calculated using a one-tailed Fisher exact test. Animals sacrificed at day 3 and day 20 postinfection were excluded from this analysis. H&E, EBER, EBNA1, EBNA2, and LMP1 staining was performed, as indicated, on a tumor in the liver (type I) of a control virus-infected animal (100ϫ magnification) (B), a tumor in the pancreas of a Z-KO virus-infected animal (type IIB) (100ϫ magnification) (C), and a tumor in the liver of a control virus-infected animal (type III) (100ϫ magnification) (D).
human immune system, lymphomas with type III latent infection inevitably develop. In this paper, we have used a new humanized mouse model to directly assess the effects of a lytic replication-defective BZLF1-deleted mutant compared to those of an otherwise identical BZLF1 ϩ control strain. We show that the lytic replication-defective mutant develops fewer lymphomas in this model. In addition, we demonstrate that this is the first humanized mouse model able to support the development of EBV-induced B cell lymphomas with restricted forms of viral latency (type I and type IIB), a feature that may be related to the presence of self-educated T cells that are able to efficiently recognize EBV-infected B cells.
We previously showed that early-passage LCLs infected with EBV are more efficient in producing LPD-like lesions in SCID mice than LCLs infected with the Z-KO virus (12) . However, the SCID mouse model does not have human immune effector populations, cannot support horizontal viral transmission, and does not contain the various different stages in human B cell differentiation. Thus, there is a critical need for the development of new, more sophisticated models to study the pathogenesis of EBV infection in vivo.
The current study is the first to comprehensively examine EBV pathogenesis in just such a system. A previous study using a similar model system showed the development of EBV-specific MHC class I-and class II-restricted adoptive immune responses (24) following infection with EBV; however, the behavior of EBV, including its ability to establish latency and form tumors, was not described. Our results showing enhanced lymphoma formation after infection by lytically active EBV suggest that horizontal transmission of virus is important for lymphoma formation, which is consistent with the findings of another group showing that the ability of EBV to induce LPD in NOD/Shi-scid/IL2r␥ null (NOG) mice following immune reconstitution with human cord blood hematopoietic stem cells (HSCs) (but not thymic tissue) is dependent on the dose of virus used to infect the mice (43) . Nevertheless, since we found that the lytic replication-defective Z-KO virus efficiently establishes viral latency in this model, another possibility is that lytically infected cells promote EBV-induced lymphomas through paracrine mechanisms and/or immunosuppressive factors.
Similar to another recent study examining EBV infection in hNSG mice (38) , we detected few if any cells with lytic EBV infection in tumor-free animals, although we found lytically infected cells within the EBV-induced tumors. In addition, we did not detect EBV DNA in the plasma of any tumor-free animal. Since the previous study found that much of the CD8 T cell response in their model is directed against lytic viral antigens (38), lytic EBV infection must clearly occur at a low level in the tumor-free animals, even if it is difficult to detect by using IHC methods or by measuring viral DNA in the plasma at the time points tested in our study. The finding that lytically infected cells are preferentially found in lymphomas in both this study and a previous study (38) is consistent with the hypothesis that lytically infected cells contribute to tumor growth through paracrine mechanisms and are thus selected for in tumors. The fact that we detected tumor cells with BZLF1 and BMRF1 expression, but not gp350/220 expression, suggests that lytic infection in tumor cells may be abortive. Interestingly, abortively lytic EBV infection which occurs shortly after EBV infection in vitro was recently reported to contribute to EBV-induced cellular proliferation of naïve and memory B cells (but not germinal center B cells) (19) . Nevertheless, detectable lytic infection in the humanized mouse model could also simply be a marker for an inadequate immune response to EBV.
Clearly, the hNSG(thy) mouse model does not always fully contain EBV infection, as evidenced by the finding that some EBV-infected mice went on to eventually develop EBV-induced lymphomas. Another technical problem with humanized mouse models in general is the tendency of the mice to develop graft-versus-host disease (GVHD) as they age. While we did not find that EBV infection affected the onset or severity of GVHD (in comparison to the mock-infected mice) in this study, the development of GVHD at late time points after immune reconstitution in this model is currently an impediment for studying EBV pathogenesis for periods longer than 2 months postinfection.
Nevertheless, several findings in the current study suggest that this model will be particularly attractive for the study of EBV-associated diseases. First, the virus is able to establish type I latency (and likely type 0 latency) in memory B cells, closely mimicking the behavior of the virus in healthy humans following recovery from primary EBV infection. Second, sim- form of latent viral infection (type III latency), suggesting that the immune response is successfully recognizing and destroying such cells. We found that primary T cells from infected hNSG(thy) mice showed specific responses to EBV-infected B cells in vitro and developed antigen-dependent DTH responses in vivo. Since the T cell responses were also present in Z-KO virus-infected animals, at least a portion of the anti-EBV immune response in the hNSG(thy) model is directed against latent viral antigens. Finally, although some animals do eventually develop EBV-positive lymphomas, only a portion of these lymphomas have type III latency (similar to EBV-induced LPD in immunosuppressed humans), whereas other lymphomas have forms of viral latency (such as type I) that occur in EBV-positive tumors of immunocompetent humans. Thus, although a variety of different approaches have been recently developed to examine EBV pathogenesis in mice with a reconstituted functional human immune system (4, 24, 38, 43) , this is the first human immune-reconstituted mouse model found to support the development of EBV-induced tumors that have type I and type IIB latency.
Interestingly, similar to the results of several other recent studies using human immune reconstituted mice (4, 43), we did not obtain EBV-positive lymphomas with type IIA latency (typical of EBV-positive Hodgkin's disease). The lack of type IIA lymphomas may reflect the fact that cells with this form of latency are very rare in the tumor-free animals (perhaps reflecting an imperfect reconstitution of the normal B cell differentiation in the lymphoid structures) and/or the requirement for multiple different cellular mutations to complement the role of EBV in such tumors. To date, NOD/SCID mice transplanted with human HSCs (and no thymus) is the only mouse model reported to support EBV-positive lymphomas with type IIA latency (16) . Since the method used to diagnose type IIA latency in this study was reverse transcription-PCR (RT-PCR) based, the results need to be confirmed by IHC staining of the tumors. In any event, since human T cells do not engraft efficiently in the NOD/SCID mouse model, NOD/ SCID mice are not useful for studying EBV pathogenesis in the context of an intact immune system. Nevertheless, our results here, as well as those of another group (4), suggest that the hNSG(thy) model should prove useful for studying other types of viral latency, particularly the type IIB form. Type IIB latency has been found in EBVinfected B cells within the tonsils of infectious mononucleosis (IM) patients (22, 27) , but currently very little is known about this type of latency. While type IIB latency has been proposed to be a marker of newly infected cells (since EBNA2 is expressed prior to LMP1 during B cell infection) (27) , our finding that Z-KO virus-infected hNSG(thy) mice have cells with type IIB latency long after the initial infection indicates that type IIB latency is not restricted to newly infected cells. Instead, since type IIB latency preferentially occurs in the follicular region of IM tonsils, whereas type IIA latency primarily occurs in the germinal centers (22) , interactions occurring between B cells and T cells within normal lymphoid structures may regulate the EBV latency state.
The development of tumors with predominantly type IIB latency in our model was unexpected and suggests that this type of latency, although nontransforming by itself, must provide some sort of survival advantage for the tumor cells. Although cells with this form of EBV gene expression pattern have been described within AIDS-associated lymphomas and posttransplant lymphoproliferative disorders (PTLDs) (9, 28) , they represent only a portion of the cells in such tumors, and it has been generally assumed that the cells with type III latency are driving the growth of such tumors. Type IIB latency also occurs following EBV infection of chronic lymphocytic leukemia (CLL) B cells in vitro (1) , but such cells are not stably results from 3 replicate samples) by effector cells from the indicated animals against the target cell types shown in the legend. The asterisks indicate the cases where no specific killing was detected. (D) Delayed-type hypersensitivity response of EBV-infected animals in response to EBV antigens. Mock-or virally infected animals were injected in the footpad with an EBV antigen preparation or with PBS. The plot shows the change in the thickness of the footpads after the antigen injection compared to preinjection measurements; the results from two mock-infected animals, four control virus-infected animals, and four Z-KO virus-infected animals are included. (Fig. 10 ) may induce CD40 signaling in the EBV-infected cells (reducing the need for LMP1 expression). In the future, it will be important to determine whether type IIB infection is more common than previously recognized during normal EBV infection in humans and what role it plays, if any, in different types of EBV-associated malignancies.
